Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0M1RD
|
|||
| Former ID |
DNCL002597
|
|||
| Drug Name |
ICT-107
|
|||
| Drug Type |
Vaccine
|
|||
| Indication | Brain cancer [ICD-11: 2A00] | Phase 3 | [1] | |
| Recurrent glioblastoma [ICD-11: 2A00.00; ICD-10: C71] | Phase 3 | [2], [3] | ||
| Glioblastoma multiforme [ICD-11: 2A00.0] | Phase 2 | [4] | ||
| Company |
ImmunoCellular Therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Interleukin 13 receptor alpha-2 (IL13RA2) | Target Info | . | [5] |
| KEGG Pathway | Jak-STAT signaling pathway | |||
| NetPath Pathway | IL4 Signaling Pathway | |||
| Panther Pathway | Interleukin signaling pathway | |||
| Pathway Interaction Database | IL4-mediated signaling events | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | ClinicalTrials.gov (NCT01280552) A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM). U.S. National Institutes of Health. | |||
| REF 5 | Clinical pipeline report, company report or official report of ImmunoCellular Therapeutics. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.